Pfizer India has announced changes to its senior management personnel, effective February 1, 2026. Mr. Nilesh Pendse has been appointed as Category Lead – Vaccines. Mr. Manikantan Seshadrinathan will transition to a new role within the Pfizer Group. Mr. Prashant Mahalingam will take on additional responsibilities as Category Lead – Internal Medicine & Hospitals.
Key Leadership Appointments
Pfizer Limited has announced several key changes within its senior management team in India, set to take effect starting February 1, 2026. These changes reflect a strategic realignment to bolster key business areas within the company.
Vaccines Division Leadership
Mr. Nilesh Pendse has been appointed as the new Category Lead – Vaccines, effective February 1, 2026. In this role, he will be a key member of the Senior Management Personnel of the Company.
Transition in Hospitals & Rare Disease
Mr. Manikantan Seshadrinathan, previously Category Lead, Hospitals & Rare Disease, will be transitioning to another role within the broader Pfizer Group of companies. This change is effective February 1, 2026, and his role as a Senior Management Personnel will conclude on January 31, 2026.
Internal Medicine & Hospitals Portfolio
Mr. Prashant Mahalingam, currently Category Lead – Internal Medicine, will expand his responsibilities to include the Hospitals business. His new designation will be Category Lead – Internal Medicine & Hospitals, effective February 1, 2026.
About Nilesh Pendse
Mr. Nilesh Pendse joined Pfizer Products India Private Limited in 2024, leading the Oncology Business. Prior to Pfizer, he held leadership roles at Boehringer Ingelheim and Novartis and has a consulting background with firms like Boston Consulting Group, Ernst & Young (EY) and Accenture. He holds an MBA in Marketing from Jamnalal Bajaj Institute of Management Studies and a Bachelor’s degree in Electronics Engineering from the University of Mumbai.
Source: BSE
